The authors

Description



Lola Svensson

Lola Svensson received her training as a biomedical scientist in Clinical Chemistry and Transfusion Medicine from the Univerisity of Gothenburg, Sweden. She defended her PhD in Clinical Chemistry on the â?•Chemical basis of ABO subgroups. Insights into blood group A subtypes revealed by glycolipid analysisâ?•. The PhD studies were focused on the chemical basis of ABO subgroups especially the blood group A subtypes revealed by glycolipid analysis. The main purpose of the project was to investigate potential structural divergences from the common A blood groups.



Serge Perez

Serge Perez was born in Perigueux, France ; he graduated, in crystallography, from the University of Bordeaux, France. He had an international exposure throughout positions in several laboratories (Institute of Molecular Biology, University of Oregon, Eugene, USA ; Department of Chemistry at the University of Montreal, Canada. Centre de Recherches sur les Macromolecules VÃ©gÃ©tales, CNRS, Grenoble, France ; Eastman Kodak, Rochester, NY, USA. Institut de la Recherche Agronomique, Nantes, France ; the European Synchrotron Radiation Facility, Grenoble, France ; Department of Molecular Pharmacochemistry, CNRS-University of Grenoble-Alpes His research interests span across

the whole area of structural and conformational analysis of oligosaccharides, polysaccharides, glycoconjugates and protein-carbohydrate interactions in solution and in the solid state. This includes interests in computational chemistry and molecular modeling, crystallography, NMR spectroscopy, along with the structure-function and structure-properties relationship. He is the author of about 300 publications in the field of structural glycosciences.



Stephen Henry

Steve Henry originally trained as a medical laboratory scientist (Immunohematologist) and later as a researcher gaining his PhDâ??s while resolving the serological, histochemical, biochemical and molecular genetic basis of several human blood group systems. Following from this academic research he became an entrepreneur and innovator of Kodeâ?¢ Technology, (www.kodecyte.com) which is now resulting in a large and increasing range of uses as an R&D toolbox, (including synthetic glycolipids) and in diagnostic products and therapeutic applications. Steve has published or presented more than 200 peer-reviewed scientific articles and is an inventor on a 27 patent family portfolio of about 120 national or regional phase applications. Steve currently holds the positions of CEO for Kode Biotech and its subsidiaries. Steve is also Professor of Innovation in the School of Engineering Computer & Mathematical Sciences at AUT University.